Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare esketamine to placebo, each in addition to standard-of-care treatment, for rapidly reducing major depressive disorder symptoms, including suicidal ideation. METHODS: This phase 3, double-blind, multicenter study (ASPIRE I), conducted between June 2017 and December 2018, enrolled 226 adults having major depressive disorder based on Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-5) criteria, active suicidal ideation with intent, and need for psychiatric hospitalization. Patients were randomized 1:1 to esketamine 84 mg or placebo nasal spray twice-weekly for 4 weeks, each with comprehensive standard-of-care treatment (initial psychiatric hospitalization and newly initiated or optimized oral antidepressant[s] therapy). Change from baseline to 24 hours post-first dose in Montgomery-Asberg Depression Rating Scale (MADRS) total score (primary endpoint) was analyzed using analysis of covariance (ANCOVA), and change in Clinical Global Impression of Severity of Suicidality Revised version (CGI-SS-r; key secondary endpoint) score was analyzed using ANCOVA on ranks with treatment difference estimated using the Hodges-Lehmann estimate. RESULTS: Greater improvement in MADRS total score was observed with esketamine + standard-of-care versus placebo + standard-of-care at 24 hours (least-squares mean difference [SE]: -3.8 [1.39]; 95% CI, -6.56 to -1.09; 2-sided P = .006), as well as at earlier (4 hours) and later time points during 4-week double-blind treatment. The difference between groups in the severity of suicidality was not statistically significant (median of treatment difference [95% CI]: 0.0 [-1.00 to 0.00]; 2-sided P = .107). The most common adverse events among esketamine-treated patients were dizziness, dissociation, headache, nausea, and somnolence. CONCLUSIONS: These findings demonstrate rapid and robust efficacy of esketamine nasal spray in reducing depressive symptoms in severely ill patients with major depressive disorder who have active suicidal ideation with intent. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03039192.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With regard to esketamine in particular, clinical use was largely based on four positive Phase 3 efficacy studies [62][63][64][65] that informed the subsequent FDA approval of intranasal esketamine for TRD and suicidal ideation with intent, as described above.”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [63]
Experimental — accuracy not yet measuredIn the citing paper
“Most recently, Fu and colleagues demonstrated moderately significant AD effects with adjunct intranasal (IN) esketamine but failed to demonstrate an effect for suicidality, the trial’s other primary outcome.”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [104]
In the citing paper
“In 2019, esketamine nasal spray (marketed as Spravato) was approved as an adjunctive AD treatment for TRD in the United States and the European Union, becoming the first novel-acting antidepressant approved in decades [104,105].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Suicide as an outcome for mental disorders: A meta-analysis
Harris, E. C., & Barraclough, B. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.170.3.205 · Cited by 2,589
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737
Kessler, R. C. (2005) · JAMA · doi:10.1001/jama.293.20.2487 · Cited by 1,073
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696
Self-citationThe European Psychiatric Association (EPA) guidance on suicide treatment and prevention
Wasserman, D., Rihmer, Z., Rujescu, D., Sarchiapone, M., Sokolowski, M., Titelman, D., Zalsman, G., Zemishlany, Z., & Carli, V. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.06.003 · Cited by 390
Deisenhammer, E. A., Ing, C.-M., Strauss, R., Kemmler, G., Hinterhuber, H., & Weiss, E. M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03904 · Cited by 315
Holma, K. M., Melartin, T. K., Haukka, J., Holma, I. A. K., Sokero, T. P., & Isometsä, E. T. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09050627 · Cited by 248
Deisenhammer, E., Ing, C.-M., Strauss, R., Kemmler, G., Hinterhuber, H., & Weiss, E. M. (2009) · PubMed · Cited by 237
Lifetime suicide risk in major depression: sex and age determinants
Blair-West, G. W., Cantor, C. H., Mellsop, G. W., & Eyeson-Annan, M. L. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00004-x · Cited by 233
Suicide Attempts Among Patients Starting Depression Treatment With Medications or Psychotherapy
Simon, G. E., & Savarino, J. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1029 · Cited by 168
Cited by
Items 101–200 of 375
Ketamine in Clinical Practice: Transitioning from Anesthetic Agent to Psychiatric Therapeutic
Quintero, J.-M., Bustos, R., Lechtig, S., Beltran, S., & Zarate, C. A. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009585330.007 · Cited by 13
Synaptic priming: A framework for pharmacotherapy in depression
Brown, K. A., Ajibola, M. I., Medeiros, G. C., & Gould, T. D. (2025) · Neuron · doi:10.1016/j.neuron.2025.09.010 · Cited by 13
Nguyen, T. M. L., Jollant, F., Tritschler, L., Colle, R., Corruble, E., & Gardier, A. M. (2023) · Pharmaceuticals · doi:10.3390/ph16040634 · Cited by 11
“Recently, two clinical trials demonstrated the rapid and robust efficacy of an esketamine nasal spray in reducing depressive symptoms in severely ill patients with major depressive disorder who were having active suicidal ideation with intent [172,173].”
Bloomfield-Clagett, B., Ballard, E. D., Greenstein, D. K., Wilkinson, S. T., Grunebaum, M. F., Murrough, J. W., Mathew, S. J., Phillips, J. L., Fava, M., Sanacora, G., et al. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac055 · Cited by 8
Self-citationRaffone, F., Mazzoni, F., Ciechi, A. D., Girone, N., Macellaro, M., Martinotti, G., Dell’Osso, B. M., Olivola, M., & Martiadis, V. (2026) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2026.104983 · Cited by 10
Chee, K. Y., Muhdi, N., Ali, N. H., Amir, N., Bernardo, C., Chan, L. F., Ho, R., Ittasakul, P., Kwansanit, P., Mariano, M. P. V., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04140-6 · Cited by 10
“Patients with MDD with active suicidal ideation with intent who received intranasal esketamine and comprehensive standard of care achieved clinically meaningful and statistically significant improvement in depressive symptoms at 24 hours post-treatment compared with placebo and comprehensive standard of care; patients…”
MethodCorral, R. M., Giraldo, E. B., Cetkovich, M., Córdoba, R., Chestaro, J., Gama, C. S., Bonetto, G. G., López‐Jaramillo, C., Moreno, R. A., Ng, B., et al. (2023) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.sjpmh.2023.06.001 · Cited by 11
The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review
Ramos, C. S., Thornburg, M., Long, K., Sharma, K., Roth, J., Lacatusu, D., Whitaker, R., Pacciulli, D., Loo, S. M., Manzoor, M., et al. (2022) · Cureus · doi:10.7759/cureus.23647 · Cited by 14
“Studies have shown that esketamine combined with an antidepressant resulted in lower depression rates than a placebo nasal spray [17-19].”
BackgroundRecent Developments in Pharmacotherapy of Depression: Bench to Bedside
Shad, M. U. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050773 · Cited by 11
Gonçalves, K. T. D. C., Tavares, V. D. D. O., Barros, M. L. D. M., de Brito, A. J. C., Cavalcanti-Ribeiro, P., Palhano-Fontes, F., Falchi-Carvalho, M., Arcoverde, E., SANTOS, R. G. D., Hallak, J. E. C., et al. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01925-6 · Cited by 13
“…treatment-resistant depression (TRD), after robust studies such as: TRANS-FORM-1 [8], TRANSFORM-2 [9], TRANSFORM-3 [10], SUSTAIN-1 [11], ASPIRE-I [12] and ASPIRE-II [13] The ketamine doses used to mediate antidepressant effects may induce an altered state of consciousness, involving…”
Making Progress in Clinical Trials for Suicide Prevention: A Review
Wilkinson, S. T., Bryan, C. J., Alphs, L. D., Canuso, C. M., Ostacher, M. J., Price, R. B., Bloch, M. H., Zarate, C. A., & Rhee, T. G. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.4810 · Cited by 7
Self-citationSpravato for Treatment-Resistant Depression: Efficacy and Sexual Side Effect Profile
Raza, A. A., Ahmed, G., Zafar, H., Akhtar, S. O., Mobin, M. B., & Samadi, A. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s548944 · Cited by 6
Rethinking the medication management of major depression
Mann, J. J., & Rizk, M. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2190886 · Cited by 10
Pompili, M., Trocchia, M. A., Longhini, L., Dispenza, E., Legge, C. D., Sarubbi, S., Erbuto, D., & Berardelli, I. (2025) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70008 · Cited by 8
Molecular Mechanisms of Depression: The Interplay Between Genes and Receptors
Oatu, A., Trifu, S. C., & Coman, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311325 · Cited by 10
“…trials showed a clinically meaningful fall in depressive symptoms and suicidal ideation 24 h after the first dose in severely ill MDD patients [197] GABAA receptor (extrasynaptic δ -containing) Zuranolone oral neuro-steroid PAM A phase-3 RCTs met the MADRS primary end-point after a 14-day,…”
Le, G. H., Wong, S., Johnson, D. E., Lu, A., Orsini, D. K., Chisamore, N., Luch, S. D. D., Rosenblat, J. D., & McIntyre, R. S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.121081 · Cited by 7
Ketamine-assisted psychotherapies for mental disorders: A historical overview and systematic review
Veraart, J. K. E., Schimmers, N., Breeksema, J. J., Seybert, C., Kamphuis, J., Huber, L. F. T., Rota, A., Coerts, D. T., Oliveira-Maia, A. J., & Schoevers, R. A. (2026) · Clinical Psychology Review · doi:10.1016/j.cpr.2026.102706 · Cited by 9
A synopsis of multitarget therapeutic effects of anesthetics on depression
Wu, G., & Xu, H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176032 · Cited by 7
Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy
Baldinger, P., Spies, M., Bozic, I., Kasper, S. F., Rujescu, D., & Frey, R. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02358-w · Cited by 9
Zhan, Z., Wang, X., Chen, Q., Xiao, Z., & Zhang, B. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043457 · Cited by 6
Rozjabek, H., Li, N., Hartmann, H., Fu, D., Canuso, C. M., & Jamieson, C. (2022) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-022-00453-y · Cited by 11
“Methods and primary data of these studies have been reported earlier [32, 33].”
BackgroundSelf-citationGutiérrez, G., Rosenblat, J. D., Hawken, E. R., Swainson, J., & Vázquez, G. H. (2022) · JMIR Research Protocols · doi:10.2196/34711 · Cited by 7
Li, J., Ma, L., Sun, H., Li, M., Cao, Y., Peng, Y., & Xu, J. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01920-x · Cited by 5
“Eight trials were included in the meta-analysis, and the other 5 studies [ 39, 41, 44, 48, 49 ] were only included in the qualitative analysis because their data were not available.”
Chen, X., Zhou, R., Lan, L., Zhu, L., Chen, C., Zhang, X., Han, J., & Xia, L. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s463028 · Cited by 5
Ramezani, F., Mardani, P., Nemati, F., Cattarinussi, G., Sambataro, F., Schiena, G., Brambilla, P., & Delvecchio, G. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.10.118 · Cited by 6
Pharmacological Strategies for Suicide Prevention Based on the Social Pain Model: A Scoping Review
Rajkumar, R. P. (2022) · Psych · doi:10.3390/psych4030038 · Cited by 5
“Fu et al., 2020 [78] Randomized controlled trial 226 patients with depression andactive suicidal ideation Intranasal esketamine (84 mg twice weekly) superior to placebo for depressive symptoms, but not suicidality.”
BackgroundResultHong, J. P., Malek, A. Z. A., Li, C., Paik, J., Sulaiman, A. H., Madriaga, G. O., Zhuo, J., Siggins, S., Fu, D., & Ju, P. (2023) · Asia-Pacific Psychiatry · doi:10.1111/appy.12548 · Cited by 5
Self-citationPompili, M., Dell’Osso, B. M., Rosso, G., Amore, M., Bellomo, A., Mautone, A., Pilotto, E., Ramacciotti, S., Scardigli, M. I., Ascione, G., et al. (2023) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2023.152430 · Cited by 5
Ketamine for Major Depressive Disorder
Costi, S. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_453 · Cited by 6
Liu, R., Liu, C., Feng, D., Guo, T., & Wang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1414703 · Cited by 7
Prevention of Suicidal Behavior in Bipolar Disorder
Tondo, L., Vázquez, G. H., & Baldessarini, R. J. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021025 · Cited by 7
Ramos‐Quiroga, J. A., Mora, F., Arostegui, S., Cardoner, N., Etxeandia-Pradera, J.-I., Gómez-Juanes, R., Gómez‐Revuelta, M., Montes, J. M. G., & Vieta, E. (2025) · The European Journal of Psychiatry · doi:10.1016/j.ejpsy.2025.100313 · Cited by 4
Li, J., Jia, G., Wang, R., Zheng, R., & Yuan, K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s553693 · Cited by 4
“Evidence suggests that intranasal esketamine is clinically useful in treating depression, 18,19 supporting the theoretical feasibility of its use in pediatric surgical settings.”
Sajid, S., Mann, J. J., & Grunebaum, M. F. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03255-0 · Cited by 10
“Some studies indicated that the observed adverse effects were consistent with the established safety pro fi le of S-ketamine nasal spray [50, 51].”
Pharmacokinetics and brain distribution of ketamine after nasal administration
Yang, Z., Li, L., Deng, B., Xu, Y., Du, Y., Lv, Y., & Zhai, X. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.116945 · Cited by 5
Huang, C., Hu, L., Wu, L., Geng, F., Wong, G. T. C., Zhang, Y., Reif, A., Bao, Y., Xue, Q., & Lü, L. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03320-6 · Cited by 17
Coulon, N., Grenon, M., Consigny, M., & Simson, J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.728133 · Cited by 5
Titone, M. K., Hunt, C., Bismark, A. W., Nokes, B. T., Lee, E., Ramanathan, D., Park, J., & Colvonen, P. J. (2023) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.10746 · Cited by 4
“Clinical trials have found that intranasal administration of esketamine also has rapid anti-depressive effects, 17,18 although meta-analyses suggest that effects may be lower than those observed with intravenous race-mic ketamine.”
Chan, E. C., Wallace, K., Yang, E. H., Roper, L., Aryal, G., Lodhi, R. J., Isenberg, R., Carnes, P. J., Baskys, A., Green, B., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114316 · Cited by 6
Lewitzka, U., Anjo, J., Annus, T., Borentain, S., Hope, K., Major, A., O’Hara, M., & Pompili, M. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.05.099 · Cited by 5
Pros and cons of esketamine treatment in psychiatry
Gutiérrez, G., & Vázquez, G. H. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.09.003 · Cited by 5
Bahji, A., Vázquez, G. H., & Zarate, C. A. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.12.069 · Cited by 5
“Given the recent publication of additional esketamine trials for suicidality and major depression (Fu et al., 2020; Ionescu et al., 2020), we are currently working on an updated meta-analysis.”
BackgroundXu, R., Pan, Y., Gorenflo, M. P., Davis, P. B., Kaelber, D. C., & Luca, S. M. D. (2023) · Research Square · doi:10.21203/rs.3.rs-3207199/v1 · Cited by 4
Nöhles, V. B., Bermpohl, F., Falkai, P., Reif-Leonhard, C., Jessen, F., Adli, M., Otte, C., Meyer‐Lindenberg, A., Bauer, M., Rubarth, K., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05230-9 · Cited by 5
Sleep alterations in treatment-resistant depression patients undergoing ketamine treatment
Kwaśny, A., Cubała, W. J., Włodarczyk, A., & Pastuszak, K. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00641-1 · Cited by 4
“Additionally, evidence indicates that esketamine nasal spray rapidly and effectively reduces depressive symptoms in patients with major depressive disorder who have severe illness and active suicidal ideation with intent [ 14, 15 ].”
Is there an independant anti-suicidal effect of esketamine in treatment resistant depression?
Danon, M., Ostronoff, G., Petit, A., de Maricourt, P., Kopeć, J. M., Mékaoui, L., Berkovitch, L., & Gorwood, P. A. P. M. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121181 · Cited by 3
Ketamine pharmacotherapy for major depressive disorder: A narrative review
Miller, C. H., Hickman, A., Baten, C., Ali, Z., Kahlon, S. K., Klassen, A. M., Zamora, G., Shepherd, J. H., Venegas, G., Miller, J. A., et al. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111651 · Cited by 3
Alphs, L. D., Fu, D., Williamson, D., Jamieson, C., Greist, J. H., Harrington, M. A., Lindenmayer, J., McCullumsmith, C. B., Sheehan, D. V., Shelton, R. C., et al. (2022) · PubMed · Cited by 6
Self-citationNew pharmacotherapies to tackle the unmet needs in bipolar disorder: a focus on acute suicidality
Kotzalidis, G. D., Fiaschè, F., Alcibiade, A., Monti, L., Segni, F. D., Mazza, M., & Sani, G. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2334425 · Cited by 4
Santucci, M. C., Katz, R. B., Pittman, B. P., Nikayin, S., & Wilkinson, S. T. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06896-7 · Cited by 3
Consistency of the Antidepressant Effect of Intranasal Esketamine in Phase 3 Clinical Trials
Preskorn, S. (2021) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000531 · Cited by 3
Bailey, A. M., Barrett, A., Havens, L., Leyder, E. C., Merchant, T., Starnes, H. M., & Thompson, S. M. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114554 · Cited by 4
Voelker, J., Sheehan, J. J., Le, H. H., Toro‐Díaz, H., Li, S., & Joshi, K. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2021-0226 · Cited by 5
Canuso, C. M., Bossie, C. A., Fu, D., Lane, R., Doherty, T., Lignugaris, A., Fagiolini, A. M., Llorca, P., McIntyre, R. S., Reif, A., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250250 · Cited by 2
Self-citationLiu, T.-H., Shen, H.-S., Wu, J., Huang, P., Shih, Y.-J., & Lai, C.-C. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04032-3 · Cited by 2
“These fi ndings extend evidence from RCTs to broader clinical populations, supporting the long-term effectiveness, safety, and potential survival bene fi t of esketamine in routine psychiatric practice.”
Schüle, C., Sobieraj, A., & Rogg, H. V. (2026) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2742-4611 · Cited by 3
“In den beiden Zulassungsstudien für intranasales Esketamin in einer Notfallindikation bei mittelgradig oder schwer depressiven Patienten mit konkreten Suizidgedanken, ASPIRE-1 [8]”
An Update on Somatic Treatments for Suicide Risk
Rizk, M., & Mann, J. J. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20260287 · Cited by 4
Chan, E. C., Wallace, K., Yang, E. H., Roper, L., Aryal, G., Lodhi, R. J., Baskys, A., Isenberg, R., Carnes, P. J., Green, B., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114128 · Cited by 3
Completed suicides and intranasal esketamine therapy: A case report and case series
Rayburn, W. F., & Albright, B. B. (2023) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2023.100104 · Cited by 7
Research trends in esketamine for depression over the past decade: a bibliometric analysis
Zhang, B., Liu, Y., Zheng, J., & Chen, J. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1621830 · Cited by 2
Chen, B. K., Jin, M., Turi, G. F., Luna, V. M., Shah, A., Moniz, T., Shannon, M. E., Pauers, M. M., Williams, B. L., Pham, V., et al. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.09.011 · Cited by 2
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.024 · Cited by 2
Borentain, S., Desai, P., Fu, D., Chen, L. N., Lane, R., Mathews, M., & Canuso, C. M. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221123046 · Cited by 7
“…suicidal ideation with intent received esketamine or placebo nasal spray, each with comprehensive standard-of-care treatment (i.e., initial psychiatric hospitalization and newly initiated or optimized oral antidepressant[s] therapy) (Canuso et al., 2018; Fu et al., 2020; Ionescu et al., 2021).”
BackgroundMethodInfluentialSelf-citationKetamine - precursor of a new generation antidepressant drugs
Zawilska, J. B., & Zwierzyńska, E. (2024) · Farmacja Polska · doi:10.32383/farmpol/186596 · Cited by 1
Gil, T., & Bonetti, T. C. (2024) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2024.100809 · Cited by 3
Vieira, F., Caliman‐Fontes, A. T., Souza‐Marques, B., Faria-Guimarães, D., Lins-Silva, D. H., Santos‐Lima, C., Jesus‐Nunes, A. P., & Quarantini, L. C. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116443 · Cited by 1
Chen, B. K., Hunsberger, H. C., Whye, A., Matthews, L. C., Yook, A., Willner, M. J., Logan, R. W., Johns, S., Weisblum, E., & Denny, C. A. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01804-9 · Cited by 3
Asrar, B., Metin, S., Sen, Z., & Ünal, G. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110650 · Cited by 1
Fountoulakis, K. Ν., Tatsiopoulou, P., Saitis, A., Fountoulakis, N. K., & Schatzberg, A. F. (2025) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-025-02897-1 · Cited by 4
“Concerning suicidality, it seems that the data are positive at 2–4 h (2/2), equivocal at 24 h (1/4), and negative at week 4 (0/6) [9, 10, 12, 23, 26, 27, 32, 52, 62, 70, 73].”
Qutishat, M., Al‐Huseini, S., & Albalushi, M. (2026) · International Journal of Mental Health · doi:10.1080/00207411.2025.2610783 · Cited by 1
“At the same time, rTMS provides a noninvasive alternative that targets specific brain areas, offering hope for patients who do not respond to traditional pharmacological therapies (Chatham et al., 2022; Li et al., 2020).”
Advances in antidepressant pharmacotherapy: phase 3 evidence and clinical perspectives
Cuomo, A., Pinzi, M., & Fagiolini, A. M. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2634195 · Cited by 1
“However, no significant differences were observed between groups regarding the severity of suicide risk during the monitoring period [46,48].”
Clinical applications of esketamine: Current status and future perspectives
Li, H., Deng, J., Liu, T., & Zhang, Y. (2026) · Journal of International Medical Research · doi:10.1177/03000605261432759 · Cited by 2
“63,64 One trial involved 226 hospitalized patients with major depressive disorder.”
An, J., Li, X., Li, Z., Wang, J., & Pan, Y. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04417-y · Cited by 5
Self-citationPharmacological and Neuromodulatory Treatments for Suicidality: A 2026 Updated Review
Medeiros, G. C., Baruzzi, M. M., Beiram, L., Roncete, G. P., de Figueiredo, L. L., Nery, L. D. D. M., Cacciacarro, M. F., Zanetti, M. V., & Damiano, R. F. (2026) · Psychiatric Annals · doi:10.3928/00485713-20260313-05 · Cited by 1
Pompili, M., Sarubbi, S., Biase, G. D., Roberto, P., Fascetti, W., Trocchia, M. A., Erbuto, D., & Berardelli, I. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.09.005 · Cited by 1
Kowalski, L., Delanogare, E., & de Oliveira, T. B. (2021) · VITTALLE - Revista de Ciências da Saúde · doi:10.14295/vittalle.v33i3.13224 · Cited by 6
Cetkovich, M., Abadi, A. F., Camino, S., Bonetto, G. G., Herbst, L., Marengo, E., Torrente, F. M., Maresca, T., Bustin, J., Morra, C. A., et al. (2023) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v34i161.488 · Cited by 2
“Sin embargo, en los cuatro ensayos que sustentan su aprobación, padecer TB ha sido utilizado como criterio de exclusión (Popova et al., 2019; Daly et al., 2019; Fu et al., 2020; Ionescu et al., 2021).”
BackgroundFrimpong, P. O. (2023) · Journal of Health, Medicine and Nursing · doi:10.7176/jhmn/111-04 · Cited by 2
Suicide and suicidal behaviors: insight into clinical challenges and preventive measures
Pompili, M., Berardis, D. D., Dell’Osso, B. M., Forte, A. M., Innamorati, M., Rogante, E., Sarli, G., Serafini, G., & Amore, M. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2542764 · Cited by 4
“The ASPIRE trials [165,166] showed that esketamine combined with a comprehensive Standard of Care (SOC) rapidly reduced depressive symptoms in MDD patients with acute suicidal ideation or behavior, especially in those with a history of suicide attempts.”
González, C. Á., Zaragozá, C., & Lopez-Munoz, F. J. (2020) · Revista de Investigación y Educación en Ciencias de la Salud (RIECS) · doi:10.37536/riecs.2020.5.2.214 · Cited by 5
Ketamine and Other Glutamate Receptor Antagonists As Fast-Actin
Chen, M., Su, T., & Tsai, S. (2022) · Neuromethods · doi:10.1007/978-1-0716-2083-0_19 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.083 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.018 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.032 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.017 · Cited by 2
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.086 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.046 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.055 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.071 · Cited by 1
Wilkowska, A., & Cubała, W. J. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01222-x · Cited by 1
“The Columbia Suicide Severity Rating Scale (C-SSRS) rating canon in this case does not apply, and dedicated psychometrics may not well represent the clinical observation that was in a way the case for the ASPIRE I and ASPIRE II studies [2, 3].”
MethodTrapp, N. T., Barbour, T. A., Kritzer, M. D., Pottanat, R., Carreon, D. M., Chen, L., Brown, J. C., & Siddiqi, S. (2023) · doi:10.31219/osf.io/m5crk · Cited by 1
Ketamine, Esketamine, and A New Generation of Antidepressants
Wilkinson, S. T., & Kitay, B. M. (2020) · Psychiatric Annals · doi:10.3928/00485713-20200113-02
Diekamp, B., Borentain, S., Fu, D., Murray, R., Heerlein, K., Zhang, Q., Schüle, C., & Mathews, M. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.09.546
Self-citationStahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.009
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.058
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.051
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.007
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.045 · Cited by 2
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.008
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.097
Metadata
- Authors
- Fu, D.-J., Ionescu, D. F., Li, X., Lane, R., Lim, P., Sanacora, G., Hough, D., Manji, H., Drevets, W. C., & Canuso, C. M.
- Affiliations
- Janssen Research & Development (United States) (US)
- Yale University (US)
- Corresponding author
- Fu, Dong-Jing
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2020-05-12
- Volume
- 81
- Issue
- 3
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- OpenAlex
- W3025905746
- Cited by
- 376
- References
- 13
- Citations by year
- 2026: 30 · 2025: 34 · 2024: 32 · 2023: 50 · 2022: 34 · 2021: 30 · 2020: 166
- FWCI
- 41.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, nasal spray, major depressive disorder, suicidal ideation, rapid-acting antidepressants, psychiatric hospitalization, antidepressant-resistant depression, depressive symptom reduction, adverse events
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Young Adult, Suicidal Ideation, Nasal Sprays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.